Study to inform COPD treatment: Novartis

Novartis has welcomed the concurrent publication and presentation of findings from the FLAME study in the New England Journal of Medicine and at the 2016 American Thoracic Society International Conference in San Francisco. The results of the study will enhance understanding of the role of dual-bronchodilation (long-acting beta-agonist [LABA] and long-acting muscarinic antagonist [LAMA] combination